1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study is crucial for understanding Tirzepatide's performance in patient groups often excluded from or underrepresented in randomized controlled trials. If successful, it could provide valuable evidence supporting…
If successful, this study could identify a simple, accessible, and enjoyable dietary intervention to optimize the benefits of GLP-1 therapy, potentially mitigating unwanted muscle loss and enhancing overall health out…
This review provides a novel mechanistic framework that integrates gut health with musculoskeletal well-being, suggesting that GLP-1 could be a pivotal therapeutic target. Understanding this "gut-GLP-1-musculoskeletal…
This study provides compelling evidence, through a robust model-informed approach, that oral semaglutide 25 mg could offer a highly effective and convenient treatment option for obesity and type 2 diabetes. The conven…
This study provides crucial evidence for policymakers, demonstrating the significant economic and health benefits of investing in comprehensive obesity management programs. By integrating more nuanced data on T2D prog…
These promising preclinical results for NeuroPep-X represent a significant step forward in the development of disease-modifying therapies for Alzheimer's Disease. The observed reductions in amyloid plaques and neuroin…
This review is crucial because it highlights the escalating global obesity crisis and the urgent need for novel, potentially safer, and more accessible therapeutic options. By systematically exploring natural products…
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting it may induce hypercapnia in susceptible individuals even with normal lung function. This finding underscores the …
The meta-analysis revealed significant improvements in metabolic parameters among kidney transplant recipients treated with GLP-1 RAs. Patients experienced a mean weight loss of 4.5 kg (p<0.001) and a reduction in HbA…
This comprehensive critique offers crucial insights for clinicians and patients, suggesting that the current evidence does not strongly support a direct causal link between GLP-1 RAs and NAION, which may help alleviat…
Preserving lean body mass during weight loss is crucial for maintaining metabolic health, physical strength, and preventing conditions like sarcopenia (age-related muscle loss). If successful, this study could provide…
This study represents a pivotal advancement in the treatment landscape for obstructive sleep apnea, offering a highly effective pharmacological approach that directly addresses a major underlying cause: obesity. The s…
If successful, this trial could identify a novel dietary supplement, AMPK Charge+®, that effectively improves glycemic control in individuals with prediabetes or Type 2 Diabetes. The potential for AMPK Charge+® to enh…
Successfully managing the gastrointestinal side effects of incretin-based anti-obesity medications is crucial for improving patient compliance and achieving optimal weight loss outcomes. This study's findings could es…
This study is crucial for understanding how lifestyle interventions like endurance exercise can complement pharmacological treatments such as semaglutide in managing Type 2 Diabetes. The key implication is that a comb…
Preserving lean muscle mass is critical for maintaining metabolic health, strength, and overall quality of life during significant weight loss. If successful, this intervention could become a standard recommendation f…
This comprehensive meta-analysis provides strong evidence that GLP-1 RAs are safe and effective for managing metabolic complications in kidney transplant recipients. The significant improvements in glycemic control, w…
This case reinforces the critical importance of considering drug-induced pancreatitis in patients presenting with acute abdominal pain while on GLP-1 receptor agonists like Semaglutide. It highlights that even at stan…
This systematic review provides strong, synthesized evidence supporting the neuroprotective potential of GLP-1 receptor agonists in Alzheimer's disease, moving beyond individual study observations. The consistent find…
These findings are profoundly significant, as they demonstrate semaglutide's potential to not only improve metabolic health and liver steatosis but also to reverse biological aging at an epigenetic level. This suggest…
This study highlights a critical safety consideration for patients undergoing free flap breast reconstruction who are also using GLP-1 RAs. The observed increase in serious wound complications, particularly flap necro…
This study provides crucial evidence supporting the economic value of Tirzepatide for a complex patient population suffering from HFpEF and obesity. These findings could significantly influence clinical guidelines, fo…
This study provides a robust, integrated safety profile for widely used GLP-1 RAs, offering a more complete picture than individual studies alone. Understanding these comprehensive safety data is crucial for informing…
This study provides crucial economic evidence for healthcare payers and policymakers in the US, suggesting that the superior efficacy of tirzepatide translates into significant long-term health benefits and a favorabl…
This study provides crucial initial evidence that KN069's novel dual mechanism—acting as a GLP-1R (glucagon-like peptide-1 receptor) agonist (mimicking a hormone that promotes insulin release and reduces appetite) and…
This research provides crucial real-world evidence suggesting that semaglutide may not only manage obesity and type 2 diabetes but also potentially offer protective or beneficial effects on skeletal health, particular…
This research highlights the profound benefits of GLP-1 receptor agonist therapy in adolescents with obesity, demonstrating not just weight reduction but a critical improvement in body composition by preferentially re…
This comprehensive meta-analysis provides compelling real-world evidence that GLP-1-based therapies offer substantial benefits beyond glycemic control and cardiovascular protection, extending to critical limb outcomes…
This study provides compelling real-world evidence that tirzepatide offers superior benefits in preventing the progression of cardiovascular-kidney-metabolic syndrome compared to other GLP-1 receptor agonists. The sig…
This study provides critical insights into the pharmacovigilance of drug-associated ketoacidosis, highlighting specific drug classes that warrant increased clinical vigilance. The strong signal for SGLT2 inhibitors re…
The widespread presence of unidentified impurities in commonly used compounded medications poses a significant patient safety risk, potentially altering the drug's efficacy, stability, or causing unforeseen adverse ef…
This study holds significant promise for improving long-term outcomes for adolescents undergoing bariatric surgery, a population often facing unique challenges in weight management. If semaglutide proves effective as …
This large-scale, real-world study is crucial for understanding the broader impact of semaglutide beyond controlled clinical trials, especially given its widespread use. The findings are expected to solidify the evide…
This Phase 4 clinical trial is crucial because it directly compares an established standard-of-care drug, metformin, with a newer, highly effective incretin therapy, semaglutide, in a real-world setting. The findings …
Developing new, potentially improved formulations of existing, effective drugs is crucial for enhancing patient convenience, adherence, and broader accessibility. If oral semaglutide D proves to be equally safe and ef…
The completion of this large Phase 3 trial is a significant milestone, as it represents a robust effort to explore a novel therapeutic avenue for Alzheimer's disease. If the results demonstrate a positive effect, it c…
Understanding the pharmacokinetic equivalence between daily and weekly dosing of semaglutide is crucial for optimizing drug development and patient care. If comparable steady-state exposure was achieved with daily adm…
Successfully demonstrating the acceptability and practicality of Tirzepatide in this population is crucial. If proven feasible, this intervention could offer a vital strategy to address obesity in breast cancer surviv…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
This study is significant because Tirzepatide could offer a novel therapeutic strategy for managing endometrial intra-epithelial neoplasia (EIN) and early-stage endometrial cancer, particularly in obese women. Given t…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…